ArticleJournal of biophotonics2014
CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer.
Article in Journal of biophotonics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- Photo- and Immunotherapy Interface: Can Dendritic Cell Vaccines Overcome the Limitations of PDT?Pharmaceutics · 2026Review
- Hypericin Photodynamic Therapy Induces Cytotoxicity and Modulates Cytokine Secretion in MCF-7 Breast Cancer Cells.Journal of clinical medicine · 2025Article
- Overcoming resistant cancerous tumors through combined photodynamic and immunotherapy (photoimmunotherapy).Frontiers in immunology · 2025Review
- Photodynamic Therapy-Induced Anti-Tumor Immunity: Influence Factors and Synergistic Enhancement Strategies.Pharmaceutics · 2023Review
- Application of Photodynamic Therapy in Pediatric Dentistry: Literature Review.Pharmaceutics · 2023Review
- Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer.Frontiers in immunology · 2023Article
- Insight into the Prospects for Tumor Therapy Based on Photodynamic Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Quickly evolving near-infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment.View (Beijing, China) · 2022Article
- Photodynamic Therapy-Mediated Immune Responses in Three-Dimensional Tumor Models.International journal of molecular sciences · 2021Review
- Progress in Nanocarriers Codelivery System to Enhance the Anticancer Effect of Photodynamic Therapy.Pharmaceutics · 2021Review
- Sendai virus-based immunoadjuvant in hydrogel vaccine intensity-modulated dendritic cells activation for suppressing tumorigenesis.Bioactive materials · 2021Article
- Progress of Phototherapy Applications in the Treatment of Bone Cancer.International journal of molecular sciences · 2021Review
- Nanomaterials-Based Photodynamic Therapy with Combined Treatment Improves Antitumor Efficacy Through Boosting Immunogenic Cell Death.International journal of nanomedicine · 2021Review
- Self-luminescent photodynamic therapy using breast cancer targeted proteins.Science advances · 2020Article
- Synergy between Photodynamic Therapy and Dactinomycin Chemotherapy in 2D and 3D Ovarian Cancer Cell Cultures.International journal of molecular sciences · 2020Article
- Article
- Preclinical and Clinical Evidence of Immune Responses Triggered in Oncologic Photodynamic Therapy: Clinical Recommendations.Journal of clinical medicine · 2020Review
- NY-ESO-1 Protein Vaccine Combining Alum, CpG ODN, and HH2 Complex Adjuvant Induces Protective and Therapeutic Anti-Tumor Responses in Murine Multiple Myeloma.OncoTargets and therapy · 2020Article
- Radiosensitization by CpG ODN7909 in an epidermoid laryngeal carcinoma Hep-2 cell line.The Journal of international medical research · 2017Article
- The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Breast cancer is the most common cause of cancer death in women. The side effects and complications following current breast cancer therapy can be devastating. Moreover, the prognosis in late stages of the diseases is usually poor. Photodynamic therapy (PDT) is a promising cancer treatment modality that is capable of both local tumor destruction and immune stimulation. However, treatment with PDT alone is often non-curative due to tumor-induced immune cell dysfunction and immune suppression. This phenomenon has motivated a new approach by combining immunostimulants with PDT to enhance anti-tumor immunity. In the present study, we investigated PDT mediated by verteporfin and 690 nm light delivered 15 min later, in combination with an immunomodulation approach using CpG oligodeoxynucleotide for the treatment of 4T1 metastatic breast cancer in a BALB/c immunocompetent mouse model. In vitro, CpG primed immature dendritic cells (DC) via toll like receptor 9 to phagocytose PDT killed tumor cells leading to DC maturation and activation. Peritumoral injection of CpG after PDT in mice gave improved local tumor control and a survival advantage compared to either treatment alone (p < 0.05). CpG may be a valuable dendritic cell targeted immunoadjuvant to combine with PDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.